Literature DB >> 11848520

Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer.

A K Joe1, N Arber, S Bose, D Heitjan, Y Zhang, I B Weinstein, H Hibshoosh.   

Abstract

African-American women with breast cancer consistently show a shortened survival when compared with Caucasians with breast cancer, however it is not clear whether this is due to socioeconomic factors or to racial differences in tumor biology. Cyclin D1 overexpression has been demonstrated in 60-80% of female breast cancers, however these studies have not included race or ethnicity data. We examined the level of cyclin D1 protein expression in 139 cases of female breast cancer obtained from different ethnic populations. Using an immunoperoxidase-based technique and a polyclonal anti-cyclin D1 antibody, the rate of overexpression was 68%. Cyclin D1 overexpression tended to be more frequent in cases from non-Caucasian patients when compared with those from Caucasian patients (77% vs. 59%, p=0.051). Our findings suggest that non-Caucasian ethnicity may be important in predicting cyclin D1 overexpression. Cyclin D1 could therefore serve as a possible target in managing breast cancer in the African-American population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11848520

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes.

Authors:  Mariana Chavez-Macgregor; Shuying Liu; Debora De Melo-Gagliato; Huiqin Chen; Kim-Anh Do; Lajos Pusztai; W Fraser Symmans; Lakshmy Nair; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam; Ana M Gonzalez-Angulo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-02       Impact factor: 4.254

2.  Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer.

Authors:  Songping Wang; Tiffany H Dorsey; Atsushi Terunuma; Rick A Kittles; Stefan Ambs; Bernard Kwabi-Addo
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.